Shots:

• Gilead will begin enrollment in P-II/III clinical trial assessing the safety- tolerability- PK and efficacy of remdesivir in ~50 pediatric patients with moderate-to-severe COVID-19- including newborns through adolescents
• The trial will be conducted at 30+ sites in the US and EU. Remdesivir is available to pediatric patients with severe COVID-19 under our compassionate use program since Feb’2020 as well as under the US FDA’s EUA
• Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro / in vivo in animal models against multiple emerging viral pathogens- including Ebola- Marburg- MERS and SARS

Click here to read full press release/ article 

Ref: Gilead | Image: Gilead

Related News: EMA to Grant Initial Authorization to Gilead’s Remdesivir for COVID-19 is Imminent